Sabrilex 500 mg granules for oral solution

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Sabrilex 500 mg granules for oral solution

Vigabatrin

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again. If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it may harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Leaflet contents

1. What Sabrilex is and what it is used for
2. What you need to know before taking Sabrilex
3. How to take Sabrilex
4. Possible side effects
5. How to store Sabrilex
6. Contents of the pack and other information

1. What Sabrilex is and what it is used for

Sabrilex is used to help control various forms of epilepsy.

It is used in addition to your current medication to treat "difficult-to-control" epilepsy. It will initially be prescribed by a specialist. Your response to treatment will be monitored.

It is also used to control infantile spasms (West syndrome).

2. What you need to know before starting Sabrilex

Do not take Sabrilex

• If you are allergic to vigabatrin or to any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Consult your doctor before starting to take Sabrilex if:

• you are breastfeeding
• you are pregnant or planning to become pregnant
• you have or have had depression or any other psychiatric illness in the past
• you have had any kidney problems
• you have had any eye problems.

If you develop symptoms such as drowsiness, decreased consciousness and movement (stupor), or confusion, consult your doctor, who will decide whether to reduce your dose or discontinue treatment.

A small number of people being treated with antiepileptic medicines such as vigabatrin have had thoughts of harming themselves or of suicide. If at any time you have these thoughts, contact your doctor immediately.

Children

Movement disorders have been reported in children treated for infantile spasms (West syndrome). If you notice unusual movement disorders in the child, consult your doctor, who will decide whether a change in treatment should be considered.

Taking Sabrilex with other medicines

Please inform your doctor if you are taking clonazepam, as its use together with Sabrilex may increase the risk of sedation.

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.

Sabrilex must not be taken in combination with other medicines that may have adverse effects related to the eyes.

Pregnancy, lactation, and fertility

If you are pregnant, think you might be pregnant, or plan to become pregnant, consult your doctor before using this medicine. Do not take Sabrilex during pregnancy unless your doctor tells you to do so. Sabrilex may cause harm to the fetus.

However, do not abruptly stop treatment, as this may endanger the health of both mother and baby.

Sabrilex passes into breast milk. If you are breastfeeding, consult your doctor before using this medicine. Breastfeeding must not be undertaken during treatment.

Driving and operating machinery

Do not drive or operate machinery if your epilepsy is not controlled.

Sabrilex may sometimes cause symptoms such as drowsiness or dizziness, and your ability to concentrate and react may be reduced. If you experience these symptoms during treatment with Sabrilex, you should not perform any potentially hazardous tasks, such as driving or operating machinery.

Visual disturbances, which may affect your ability to drive or operate machinery, have been reported in some patients taking this medicine. If you wish to continue driving, you should have regular examinations (every six months) to rule out the presence of visual disturbances, even if you do not notice any changes in your vision.

3. How to take Sabrilex

Follow exactly the instructions given by your doctor for taking this medicine. If in doubt, consult your doctor again.

It is important to follow your doctor's instructions precisely. Never change the dose.

Your doctor will prescribe and individually adjust the dose for each patient.

Do not open the sachets until it is time to take your medicine. To take a dose, dissolve all the powder from the number of sachets recommended by your doctor in half a glass of cold water or soft drinks such as fruit juice or milk. Once all the powder has dissolved, drink the entire solution without leaving any residue. Sabrilex may be taken before or after meals.

The recommended starting dose is 1 g (2 sachets) per day. However, your doctor may increase or decrease the dose depending on your response to treatment; the usual daily dose for adults is 2 to 3 g (4 to 6 sachets). The maximum recommended dose is 3 g per day.

If you are an elderly patient and/or have kidney problems, your doctor will prescribe a lower dose.

Use in children

Resistant partial epilepsy

In children, the dose is based on age and body weight. The recommended starting dose is 40 milligrams per kilogram of body weight per day. The following table indicates the number of sachets to be administered to children according to their body weight. Please remember that this is only a guide. The child's doctor will decide whether to prescribe a slightly different dose.

Weight 10-15 kg 0.5-1 g (1-2 sachets)/day

15-30 kg 1-1.5 g (2-3 sachets)/day

30-50 kg 1.5-3 g (3-6 sachets)/day

Over 50 kg 2-3 g (4-6 sachets)/day (adult dose)

Infants with infantile spasms (West Syndrome)

The recommended starting dose for infants with West Syndrome (infantile spasms) is 50 milligrams per kilogram of body weight per day, although higher doses may sometimes be used.

Method of administration

The route of administration is oral (by mouth).

Always swallow the tablet with at least half a glass of water.

Sabrilex may be taken before or after meals.

The daily dose may be taken as a single dose or divided into two doses.

If you take more Sabrilex than you should

If you or your child accidentally take too many Sabrilex sachets, contact your doctor immediately or go to the nearest hospital emergency department, bringing this leaflet with you.

In case of overdose or accidental ingestion, contact the Toxicology Information Service. Telephone 91 562 04 20.

Possible symptoms of overdose include drowsiness or loss/reduction in level of consciousness.

If you forget to take Sabrilex

If you forget to take a dose, take it as soon as you remember. If it is almost time for your next dose, take only one dose. Do not take a double dose to make up for forgotten doses.

If you stop taking Sabrilex

Do not stop taking this medicine without consulting your doctor. If your doctor decides to discontinue your treatment, they will give you instructions on how to gradually reduce the dose. Do not stop abruptly, as this may cause your seizures to return.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine may cause adverse effects, although not everyone gets them.

As with other antiepileptic medicines, some patients may experience an increase in the number of seizures while taking this medicine. If this happens to you or your child, contact your doctor immediately.

Contact your doctor immediately if you experience:

Very common adverse effects (may affect more than 1 in 10 patients)

• Changes in visual field – Approximately 1/3 or 33 percent of patients treated with Sabrilex may experience changes in visual field (constriction of visual field). These "visual field defects" can range from mild to severe. These are usually detected after months or years of treatment with Sabrilex. Visual field changes may be irreversible, so early detection is essential. If you or your child experiences any visual disturbances, contact your doctor or hospital immediately.

Other adverse effects include:

Very common adverse effects (may affect more than 1 in 10 patients)

• Tiredness and marked drowsiness
• Joint pain

Common adverse effects (may affect up to 1 in 10 patients)

• Headache
• Weight gain
• Tremor
• Swelling (edema)
• Dizziness
• Numbness or tingling sensation
• Concentration and memory disorders
• Psychological disorders, including agitation, aggression, nervousness, irritability, depression, thought disorders and paranoid reactions (progressive mental disorder), insomnia. These adverse effects are generally reversible by reducing the dose or gradually discontinuing treatment. However, do not reduce your dose without first consulting your doctor. Contact your doctor if you experience these adverse effects.
• Nausea, vomiting and abdominal pain
• Blurred vision, double vision and involuntary rapid eye movements
• Speech disorders
• Decrease in the number of red blood cells (anaemia)
• Unusual hair loss or weakened hair (alopecia)

Uncommon adverse effects (may affect up to 1 in 100 patients)

• Lack of coordination in movements, clumsiness
• More severe psychological disorders such as hypomania, mania and psychosis
• Skin rash

Rare adverse effects (may affect up to 1 in 1,000 patients)

• Severe allergic reaction causing swelling of the face or swelling of the throat. If you experience any of these symptoms, inform your doctor immediately
• Hives (urticaria)
• Marked sedation, stupor and confusion. These adverse effects are usually reversible by reducing the dose or gradually discontinuing treatment. However, do not reduce your dose without first consulting your doctor. Contact your doctor if you experience these adverse effects.
• Suicidal attempt
• Other eye disorders such as retinal disorders

Very rare adverse effects (may affect up to 1 in 10,000 patients)

• Other eye disorders such as optic neuritis and optic atrophy
• Hallucinations
• Liver disorders

Adverse effects with unknown frequency (frequency cannot be estimated from available data)

• Decreased visual acuity
• Abnormal changes in brain images obtained by magnetic resonance imaging (MRI)
• Swelling in the protective layer of nerve cells in part of the brain, as seen on magnetic resonance imaging.

Other adverse effects in children

Very common adverse effects (may affect more than 1 in 10 children)

• Excitation or restlessness

Adverse effects with unknown frequency (frequency cannot be estimated from available data)

• Movement disorders in children treated for infantile spasms
• Abnormal changes in brain images obtained by magnetic resonance imaging, particularly in infants
• Swelling in the protective layer of nerve cells in part of the brain, as seen on magnetic resonance imaging.

Reporting of adverse effects:

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Sabrilex

Keep this medicine out of sight and reach of children.

Do not use this medicine after the expiry date stated on the carton and sachets. The expiry date is the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Dispose of empty containers and unused medicines at the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to properly dispose of containers and unused medicines. This will help protect the environment.

6. Contents of the container and other information

Composition of Sabrilex

• The active substance is vigabatrin. One sachet contains 500 mg of vigabatrin.
• The other components are:

Povidone K30 (E1201).

Appearance of the medicinal product and contents of the container

Sabrilex granules for oral solution is a white to off-white granular powder.

It is available in packs of 50, 60, or 100 sachets.

Only certain pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

The marketing authorization holder is:

sanofi-aventis, S.A.

C/ Rosselló i Porcel, 21

08016 Barcelona

Spain

The manufacturer is:

Patheon France

Boulevard de Champaret

38300 Bourgoin-Jallieu (France)

Or

Sanofi-Aventis Deutschland GmbH

Industriepark Hoechst-Brueningstrasse 50

65926 Frankfurt am Main (Germany)

This medicinal product is authorized in the European Economic Area member states under the following names:

Austria: Sabril 500 mg lösliches Pulver
Denmark: Sabrilex
Finland: Sabrilex 500 mg rakeet oraaliliuosta varten
France: Sabril 500 mg granulés pour solution buvable en sachet-dose
Germany: Sabril Beutel
Ireland: Sabril 500 mg granules for oral solution
Italy: Sabril 500 mg granulato per soluzione orale
Netherlands: Sabril 500 mg granulaat voor drank
Portugal: Sabril 500 mg granulado para soluçào oral
Spain: Sabrilex 500 mg granulado para solución oral
Sweden: Sabrilex 500 mg granulat till oral lösning
United Kingdom: Sabril 500 mg granules for oral solution

Date of the most recent review of this leaflet: August 2025

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es/